Galmed Pharmaceuticals Ltd. is a clinical stage biopharmaceutical company focused on the development of Aramchol for liver and fibro-inflammatory diseases. The company has focused almost exclusively on developing Aramchol for the treatment of NASH and are currently developing Aramchol for PSC and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of liver disease. Galmed Pharmaceuticals is also collaborating with the Hebrew University in the development of Amilo-5MER, a 5 amino acid synthetic peptide.